Oncotype DX is the preferred validated multigene assays to predict the benefits of chemotherapy in HR+/HER2‐, node‐negative breast cancer,22, 23 as well as in HR+/HER2‐ limited node‐positive (N1) breast cancer.22, 24, 25. Here, ERBB2 is linked to breast carcinoma.